Amylx Pharmaceuticals Inc vs Intuit Inc. — how do they compare? Amylx Pharmaceuticals Inc trades at $23.96 (market cap $2.64B), while Intuit Inc. trades at $332.01 (market cap $92.03B). The key difference: Intuit Inc. is far larger — about 34.9× Amylx Pharmaceuticals Inc's market cap, and Intuit Inc. pays a 1.43% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | INTU | |
|---|---|---|
Market Cap | $2.64B | $92.03B |
Sector | Health | Technology |
52-Week High | $24.19 | $717.21 |
52-Week Low | $7.82 | $255.07 |
Enterprise Value | $2.39B | $90.49B |
Dividend Yield | — | 1.43% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Intuit (INTU) trades at $334.43, up 2.82% today, with a bullish technical signal from moving averages and strong fundamental performance. Recent earnings beats, including Q1 2026 EPS of $12.8 versus $12.57 expected, highlight robust profitability. However, the stock faces headwinds from legal investigations into pricing disclosures and a recent 20% drop, as reported by Forbes on June 2, 2026.
The outlook is mixed: analyst consensus targets $402.26 (66.7% buy ratings), but legal risks and overbought RSI levels near 74.42 suggest caution. Revenue growth to $20.9B in 2026 and a high net margin of 21.9% support long-term value, yet near-term volatility may persist due to sentiment shifts.
Trailing returns across standard periods
Latest headlines on both assets
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →Intuit is a provider of small-business accounting software (QuickBooks), personal tax solutions (TurboTax), and professional tax offerings (Lacerte). Founded in the mid-1980s, Intuit controls the majority of U.S. market share for small-business accounting and DIY tax-filing software.
Read more on INTU →